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L. Azas,2 C. Pratesi,2 G.F. Gensini1 and R. Abbate11Department of Clinical and Surgical Critical Care, Thrombosis Centre, Center for the Study at Molecular and
Clinical Level of Chronic, Degenerative and Neoplastic Diseases to Develop Novel Therapies, 2Unit of Vascular
Surgery, Department of Clinical and Surgical Critical Care, and 3Unit of Medical Genetic, Department of
Clinical Pathophysiology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, ItalyObjective. To examine the role of polymorphisms in angiotensin converting enzyme (ACE, I/D) and angiotensin II receptor
(AT1R, A1166C) in the development of abdominal aortic aneurysm (AAA).
Materials and methods. We investigated 250 consecutive patients, 217 males and 33 females (median age 72, range 50–
83), undergone AAA elective repair and 250 healthy controls, comparable for sex and age. ACE and AT1R polymorphisms
were studied by PCR-RFLP analysis. The genotype distribution was in Hardy–Weinberg equilibrium for all polymorphisms.
Results. The genotype distribution and allele frequency of ACE I/D, but not AT1R A1166C polymorphism were
significantly different between patients and controls (ACE I/D: pZ0.0002 and p!0.0001, respectively, and AT1R A1166C:
pZ0.6 and pZ0.4, respectively). An association between the ACE DD genotype and the predisposition to AAA was found
(OR DD vs. IDCIIZ1.9 95% CI 1.3–2.9, p!0.0001). Multivariate analysis adjusted for age, sex, traditional vascular risk
factors and other atherosclerotic localizations, showed ACE DD genotype to be independently related to the disease (OR DD
vs. IDCIIZ2.4, 95% CI 1.3–4.2 pZ0.003).
Conclusions. Our findings document that ACE DD genotype represents a susceptibility factor for AAA.Keywords: ACE polymorphisms; Abdominal aortic aneurysm; Genetic risk factors.Introduction
Abdominal aortic aneurysm (AAA) represents a
chronic degenerative condition associated with ather-
osclerosis and characterized by segmental weakening
and dilation of the aortic wall. Its pathogenesis
involves both genetic and environmental factors, but
it has not been completely clarified yet. Experimental
studies demonstrate that angiotensin II infusion
produces large abdominal aortic aneurysm1 in ani-
mals. Both angiotensin II-forming enzymes, chymase
and angiotensin converting enzyme (ACE), are highly
expressed in human aneurysmal aorta.2 Accordingly,
increased local angiotensin II formation may play a
crucial role in the development of the disease.ing author. Dr Giovanni Pratesi, Department of
ery, University of Florence, Viale Morgagni 85, 50134
y.
: vasc@unifi.it
0227+ 06 $35.00/0 q 2004 Elsevier Ltd. All rights reserThe I/D polymorphism in the intron 16 of the
angiotensin converting enzyme (ACE) gene and the
A1166C polymorphism in the gene encoding for
angiotensin II type 1 receptor (AT1R) have been
demonstrated to be associated with atherosclerotic
lesions in cardiovascular disease.3 The ACE D allele
has been reported to be associated with increased
serum levels of circulating enzyme4 and behaves like a
marker of atherosclerotic cardiovascular compli-
cations.5,6 The 1166C rare variant of the A1166C
polymorphism has been associated with aortic stiff-
ness7,8 and vascular reactivity,9 suggesting a biological
effect possibly through linkage disequilibrium with
another functional polymorphism.
To the best of our knowledge, no data are available
regarding the evaluation of ACE andAT1R polymorph-
isms inpatients affectedbyAAA.This studywas carried
out inorder todocument a role for thesepolymorphisms
in the pathogenesis of artery aneurysm and to evaluate
their role in normo- and hypertensive patients.Eur J Vasc Endovasc Surg 29, 227–232 (2005)
doi:10.1016/j.ejvs.2004.12.018, available online at http://www.sciencedirect.com onved.
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We studied 250 consecutive patients with AAA
referred to the Unit of Vascular Surgery of the
University of Florence. AAA was defined as a focal
dilation of the abdominal aorta at least 50% larger than
expected normal diameter, according to the current
report standard.10 Consanguineous subjects and
inflammatory aneurysms were excluded from the
study. A group of 250 healthy subjects recruited from
partners or friends of patients and comparable for age
and gender were used as controls. All controls had no
AAA and a negative history of vascular diseases, as
evaluated by expert physicians in the frame of the
physical examination. Patients and controls were
Caucasians from central and southern Italy. All
subjects gave informed consent. The study was
approved by the local ethics committee. All subjects
underwent duplex scanning examination using an
Acuson Sequoia Color Duplex System (Mountain
View, CA, USA) with a multifrequency convex
probe, ranging from 5 to 2 MHz. Ultrasound scanning
examination was then confirmed in patients by CTA.
Digital subtraction angiography was performed only
in patients with concomitant peripheral arterial dis-
ease and in candidates for endovascular treatment of
AAA when CTA was not satisfactory to evaluate the
feasibility for endovascular treatment. Aortic diameter
wasmeasured below the origin of renal arteries in both
groups. The subjects were considered to have hyper-
tension if they had been diagnosed as hypertensives
according to the guidelines of European Society of
Hypertension/European Society of Cardiology11 or
were taking antihypertensive drugs. Dyslipidemia
was defined according to the Third report of the
National Cholesterol Education Program (NCEP-III)12
and diabetes in agreement with the American Diabetes
Association.13
All patients underwent clinical examinations, elec-
trocardiography, echocardiography and duplex scan-
ning of carotid arteries and ankle/brachial pressure
index evaluation. In patients with symptoms of
ischemic heart disease, further investigations were
performed (echocardiography on drug-induced stress
testing, myocardial scintigraphy, and coronary angio-
graphy). The severity of carotid stenosis, confirmed by
computed tomography angiography, was defined
according to the NASCETcriteria.14 Peripheral arterial
disease was documented as present if ankle/brachial
pressure index was less than 0.9. On the basis of these
criteria 71 (28%) patients had clinical evidence ofEur J Vasc Endovasc Surg Vol 29, March 2005coronary artery disease (CAD), cerebrovascular dis-
ease (CVD) was found in 25 patients (10%) and
peripheral arterial disease (PAD) in 49 (19%). Aneur-
ysmal size was measured by means of computed
tomography.Detection of ACE and AT1R polymorphisms
Genomic DNA extraction was performed from per-
ipheral blood leucocytes by using a QIAmp Blood Kit
(QIAGEN, Hilden, Germany).
The ACE I/D polymorphism was genotyped
according to Rigat et al.15 The DD genotype was
subjected to a second PCR amplification without 5%
DMSO at an annealing temperature of 67 8C and by
using a primer pair that recognises the insertion-
specific sequence, in order to reduce underestimation
of heterozygotes.16 The ACE I/D polymorphism
consists of the presence/absence of a 287 bp DNA
fragment corresponding to an Ala repetitive sequence
in the intron 16 of the ACE gene, so determining the
insertion (I) and deletion (D) allele. This polymorph-
ism accounts for three genotypes, DD and II homo-
zygotes and ID heterozygote. Because the alleles are
codominant with an additive effect on plasma levels,
subjects homozygote for the deletion allele have the
highest ACE plasma levels, the homozygotes for the
insertion allele have the lowest and subjects hetero-
zygotes ID show intermediate levels. The A1166C
polymorphism of the AT1R gene was identified by
PCR amplification using primers and PCR conditions
as described by Katsuja et al.17Statistical analysis
Statistical analysis was performed by using the
Statistical Package of Social Sciences (SPSSw; Chicago,
IL, USA) software forWindows (Version 11.5). Data are
expressed as median and range. Aortic diameter was
expressed as meanGSD. The c2-test was used to test
for proportions and deviations of genotype distri-
bution from Hardy–Weinberg equilibrium. ACE and
AT1R allele frequencies were obtained by direct count.
The number of subjects studied was sufficient to
detect, with a statistical power of 80% (bZ0.8) and
significance value of 0.05 (a), absolute difference in
ACE allele frequency. We used a recessive model of
inheritance, which assumed the rare allele to be
dominant (e.g. ACE DD vs. IDCII). The non-para-
metric Mann–Whitney test was used for comparisons
between single groups. Kruskal–Wallis test was used
for comparisons among different groups. The relation-
ship between the two polymorphisms and AAA was
Table 1. Demographic characteristics and traditional risk factors
for vascular disease of study population
Variable Patients
(nZ250)
Healthy subjects
(nZ250)
P value
Age (years)* 72 (50–83) 71 (49–87) 0.06
Males, n (%) 217 (86.8) 216 (86.4) 0.9
Females, n (%) 33 (13.2) 34 (13.6) 0.8
Hypertension, n (%) 185 (74) 48 (19.2) !0.0001
Dyslipidemia, n (%) 107 (42.8) 36 (14.4) !0.0001
Smoking habit, n (%) 180 (72) 62 (24.8) !0.0001
Abdominal aortic
diameter (cm)†
6.5G1.3 1.7G1.1 !0.0001
* Median and (range).
† MeanGSD.
ACE Polymorphisms and Abdominal Aortic Disease 229determined by univariate logistic regression analysis.
Variables showing, at univariate analysis, a statisti-
cally significant association with AAA were intro-
duced in a multivariate model in order to evaluate the
association with the disease after adjustment for
traditional cardiovascular risk factors. Odds ratio
(OR) with 95% confidence interval was determined.
A p-value!0.05 was considered to indicate statistical
significance.Results
Demographic and clinical characteristics of the study
population are described in Table 1. We observed
significant differences between the two groups for
traditional cardiovascular risk factors. Genotype dis-
tribution and allele frequency of ACE I/D and AT1R
A1166C polymorphisms were in Hardy–Weinberg
equilibrium and are reported in Table 2.
A significant difference in both genotype distri-
bution and allele frequency between patients and
healthy subjects was observed for ACE, but not for
AT1R polymorphism.
Univariate logistic regression analysis demon-
strated an association of ACE DD genotype and the
disease (Table 3) (p!0.0001). By determining the odds
ratios on the basis of the number of rare alleles, weTable 2. Genotype distribution and allele frequencies of ACE and A
Genotype Allele Patients (nZ250) n,
ACE II 38 (15.2)
ACE ID 108 (43.2)
ACE DD 104 (41.6)
D 0.63
AT1R AA 120 (48)
AT1R AC 108 (43.2)
AT1R CC 22 (8.8)
C 0.30
ACE II, subjects homozygotes for the ACE I allele; ACE ID, subjec
allele; AT1R AA, subjects homozygotes for the AT1R A allele; AT1R
the AT1R C allele.observed an increased predisposition to AAA with a
dose-dependent effect for ACE but not for AT1R
polymorphism (Table 3). Adjusting for age, gender,
smoking habit, hypertension, dyslipidemia and other
atherosclerotic disease (i.e. CAD, PAD and CVD)
(Table 4), ACE DD genotype was still significantly
associated with AAA. The contemporary presence of
ACE D and AT1R C alleles did not influence the
predisposition to AAA [OR ACE DDC AT1R CC vs.
(IDCII)C(ACCAA)Z1.83 95% CI 0.60–5.54, pZ0.3].
As far as hypertension is considered, a significant
difference between hypertensive AAA patients and
hypertensive controls (pZ0.04), as well as between
normotensive AAA patients and normotensive con-
trols (pZ0.0002) was found. We observed no signifi-
cant difference (pZ0.2) in the ACE D allele frequency
between hypertensive and normotensive patients and
hypertensive and normotensive controls (pZ0.8)
(Table 5).
Aortic diameters were similar among the three
genotypes both in ACE and in AT1R polymorphisms
and no significant difference in diameters among the
subgroups was observed (Table 6). The mean diameter
of abdominal aorta in hypertensive patients (6.1G1.2)
was comparable (pZ0.4) to that observed in normo-
tensive patients (5.9G1.3).Discussion
The present study evaluated for the first time the role
of both ACE and AT1R genes in the predisposition to
AAA. Our results confirmed the role of traditional
vascular risk factors (i.e. smoking habit, hypertension
and dyslipidemia) in the predisposition to AAA, and
provide evidence for a mild, but significant, associ-
ation with the disease in subjects carrying the ACE D
allele. Conversely, we failed to find such a similar
influence as regard the AT1R A1166C polymorphism.
ACE D allele has been reported to affect plasma
ACE levels,4 since I allele may have a ‘silencer’ effect,18T1R polymorphisms
(%) Healthy subjects (nZ250) n, (%) p value
70 (28)
113 (45.2)
67 (26.8) 0.002
0.49 !0.0001
125 (50)
109 (43.6)
16 (6.4) 0.6
0.28 0.4
ts heterozygotes; ACE ID, subjects homozygotes for the ACE D
AC, subjects heterozygotes; AT1R CC, subjects homozygotes for
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Table 3. ACE and AT1R polymorphisms and predisposition to
AAA—(univariate analysis)
OR 95% CI p value
ACE DD vs.
IDCII
1.9 1.3–2.9 !0.0001
ACE ID vs. II 1.76 1.09–2.83 0.002
ACE DD vs. II 2.86 1.73–4.72 !0.0001
AT1R CC vs.
ACCAA
1.41 0.72–2.76 0.3
AT1R AC vs.
AA
1.03 0.72–1.49 0.8
AT1R CC vs.
AA
1.43 0.72–2.86 0.3
IDCII, subjects heterozygotes for the ACE D allele plus subjects
homozygotes for the ACE I allele; ACCAA, subjects heterozygotes
for the AT1R C allele plus subjects homozygotes for the AT1R A
allele.
Table 4. Multivariate logistic regression analysis on the predis-
position to AAA
Adjusted* OR 95% CI p value
Age 1.03 0.9–1.07 0.06
Gender (males
vs. females)
1.2 0.6–2.5 0.6
Smoking habit 8.2 4.9–13.5 !0.0001
Hypertension 11.4 6.9–18.9 !0.0001
Dyslipidemia 2.3 1.3–4.2 0.004
ACE DD vs.
IDCII
2.4 1.3–4.2 0.003
* Adjusted for age, gender, smoking habit, hypertension, dyslipi-
demia and other atherosclerotic localizations (CAD, PAD, CVD).
C. Fatini et al.230thereby regulating the production of angiotensin II
with a dose-dependent effect (i.e. ID genotype have
higher ACE plasma levels than II whereas DD
genotype have higher ACE plasma levels than both
ID and II genotypes).
DD homozygotes subjects had higher levels of ACE
compared to II homozygotes, and intermediate levels
were observed in heterozygotes ID.4 Increased angio-
tensin II plasma levels may lead to the remodelling of
vascular tissue.19 However, the mechanisms respon-
sible for aortic dilation remain to unknown. Exper-
imental data demonstrates a relationship between
angiotensin II, atherosclerosis, and aortic aneurysm
formation.1 Angiotensin II promotes hypertension andTable 5. ACE and AT1R distributions and allele frequencies both in
Genotype Hypertensive AAA (nZ
182), group a
Hypertensive
(nZ48), grou
ACE DD 77 (42.3) DD 13 (27.1)
ID 71 (39) ID 22 (45.8)
II 34 (18.7) II 13 (27.1)
ACE D allele frequency 0.62* 0.50
AT1R AA 81 (44.5) AA 25 (52)
AC 83 (45.6) AC 22 (45.8)
CC 18 (9.9) CC 1 (2)
AT1R C allele frequency 0.33 0.25
* P for ACE D allele frequency: group a vs. group b pZ0.04.
† P for ACE D allele frequency: group c vs. group d pZ0.0002.
Eur J Vasc Endovasc Surg Vol 29, March 2005alters shear stress.20,21 Another mechanism by which
angiotensin II may affect the vascular tissue remodel-
ling is the activation of growth factors and inflam-
mation either through the induction of cytokines and
VCAM-1 expression,22 or by activating NF-kB-depen-
dent gene expression,23 or probably by inducing MCP-
1 (monocyte chemoattractant protein-1), a product of
endothelial and smooth muscle cells expression.
Our results are in keeping with those reported by
Pola et al. in Italian population,24 but at variance with
those of a Japanese study.25 These conflicting findings
might be a result of the variable impact that a
polymorphism can have on populations with different
genetic background. Our data confirms previous
results which identified the ACE DD genotype as a
risk factor for both cardiac and carotid atherosclero-
sis.26,27 Pola et al.24 suggested a role for ACE I/D
polymorphism in the pathogenesis of AAA in normo-
tensive, but not in hypertensive patients; however, our
findings provide evidence of an influence of ACE I/D
polymorphism on pathogenesis of AAA, both in
normotensive and in hypertensive patients. Hyperten-
sion is a known risk factor for AAA and data from
literature report conflicting results about the associ-
ation between ACE I/D polymorphism and hyperten-
sion.28,29
In our opinion the new feature of our study is the
contemporary evaluation of two different genes in the
predisposition to AAA. We evaluated the relationship
between the ACE and AT1R genes polymorphisms
and the aortic diameter, but we did not demonstrate
any difference in AAA dilation among genotypes
analysed. Yeung et al.30 failed to find any relationship
between ACE gene and rate of AAA expansion; they
hypothesised that other components of the RAS may
play a role in AAA progression. However, our study,
which analysed the relationship between the other
components of RAS, such as AT1R gene, and aortic
dilation, did not support this hypothesis.
Some limitations can be identified in this study.
First, because of its case–control design, the study ishypertensives and in normotensives
controls
p b
Normotensive AAA
(nZ68), group c
Normotensive controls
(nZ202), group d
DD 28 (41.2) DD 54 (26.7)
ID 36 (52.9) ID 91 (45)
II 4 (5.9) II 57 (28.2)
0.68† 0.49
AA 38 (55.9) AA 100 (49.5)
AC 26 (38.2) AC 87 (43.1)
CC 4 (5.9) CC 15 (7.4)
0.25 0.29
Table 6. Aortic diameters in ACE and AT1R polymorphisms
Genotype Patients (nZ250), (meanGSD) p for trend
ACE II 6.1G1.3
ACE ID 5.9G1.1 0.1
ACE DD 6.2G1.5
AT1R AA 6.1G1.3
AT1R AC 6.0G1.3 0.3
AT1R CC 5.7G0.9
Values are expressed in cm.
ACE Polymorphisms and Abdominal Aortic Disease 231unable to determine if ACE polymorphism is causally
related to the presence of AAA. The clinical signifi-
cance of the association between ACE polymorphism
and AAA needs to be confirmed by further studies.
Secondly, the control group consisted of clinically
healthy subjects with no evidence of atherosclerotic
disease whereas the optimal comparable control group
would be represented by atherosclerotic subjects with
no AAA.
In conclusion, this study shows that ACE DD
genotype represents a marker of increased suscepti-
bility to AAA. Our results, according to other
experimental and clinical studies,31,32 could suggest a
possible benefit of ACE inhibitors treatment in
increasing type III collagen turnover and in AAA
wall matrix remodelling, apart from hypertension. The
clinical relevance of these findings lays in the possible
identification of patients with AAA carrying the ACE
D allele, who may exhibit a better response to ACE
inhibitors drugs,33 in order to perform a tailored
medical therapy.
Moreover, future prospective study testing the
contribution of ACE and AT1R genes in determining
the rate of AAA dilation would be worthwhile.References
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